Wayne A Beckham

Dr. Wayne A Beckham


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
WBWayne A Beckham
Wayne A Beckham
CPCarmen C. Popescu
Carmen C. Popescu
VPVeronica V. Patenaude
Veronica V. Patenaude
EWElaine S. Wai
Elaine S. Wai
IOIvo A. Olivotto
Ivo A. Olivotto

16 September 2002 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
WBWayne A Beckham
Wayne A Beckham
PKP J Keall
P J Keall
JSJ V Siebers
J V Siebers
The International Commission on Radiation Units and Measurements Report 62 (ICRU 1999) introduced the concept of expanding the clinical target volume (CTV) to form the planning target volume by a two-step process. The first step is adding a clinically definable internal margin, which produces an internal target volume that accounts for the size, shape and position of the CTV in relation to anatomical reference points. The second is the use of a set-up margin (SM) that incorporates the uncertainties of patient beam positioning, i.e. systematic and random set-up errors. We propose to replace the random set-up error component of the SM by explicitly incorporating the random set-up error into the dose-calculation model by convolving the incident photon beam fluence with a Gaussian set-up error kernel. This fluence-convolution method was implemented into a Monte Carlo (MC) based treatment-planning system. Also implemented for comparison purposes was a dose-matrix-convolution algorithm similar to that described by Leong (1987 Phys. Med. Biol. 32 327-34). Fluence and dose-matrix-convolution agree in homogeneous media. However, for the heterogeneous phantom calculations, discrepancies of up to 5% in the dose profiles were observed with a 0.4 cm set-up error value. Fluence-convolution mimics reality more closely, as dose perturbations at interfaces are correctly predicted (Wang et al 1999 Med. Phys. 26 2626-34, Sauer 1995 Med. Phys. 22 1685-90). Fluence-convolution effectively decouples the treatment beams from the patient. and more closely resembles the reality of particle fluence distributions for many individual beam-patient set-ups. However, dose-matrix-convolution reduces the random statistical noise in MC calculations. Fluence-convolution can easily be applied to convolution/superposition based dose-calculation algorithms.

9 March 2000 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
SMS D McCarter
S D McCarter
WBWayne A Beckham
Wayne A Beckham
Modern radiotherapy techniques have developed to a point where the ability to conform to a particular tumour shape is limited by organ motion and set-up variations. The result is that dose distributions displayed by treatment planning systems based on static beam modelling are not representative of the dose received by the patient during a fractionated course of radiotherapy. The convolution-based method to account for these variations in radiation treatment planning systems has been suggested in previous work. The validity of the convolution method is tested by comparing the dose distribution obtained from this convolution method with the dose distribution obtained by summing the contribution to the total dose from each fraction of a fractionated treatment (for increasing numbers of fractions) and simulating random target position variations between fractions. For larger numbers of fractions (approximately or > 15) which are the norm for radical treatment schemes, it is clear that incorporation of movement by a convolution method could potentially produce a more accurate dose distribution. There are some limitations that have been identified, however, especially in relation to the heterogeneous nature of patient tissues, which require further investigation before the technique could be applied clinically.

22 May 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NJNolan Jackson
Nolan Jackson
DCDaniel Cecchi
Daniel Cecchi
WBWayne A Beckham
Wayne A Beckham
DCDevika Chithrani
Devika Chithrani
Radiotherapy is an essential component of the treatment regimens for many cancer patients. Despite recent technological advancements to improve dose delivery techniques, the dose escalation required to enhance tumor control is limited due to the inevitable toxicity to the surrounding healthy tissue. Therefore, the local enhancement of dosing in tumor sites can provide the necessary means to improve the treatment modality. In recent years, the emergence of nanotechnology has facilitated a unique opportunity to increase the efficacy of radiotherapy treatment. The application of high-atomic-number (Z) nanoparticles (NPs) can augment the effects of radiotherapy by increasing the sensitivity of cells to radiation. High-Z NPs can inherently act as radiosensitizers as well as serve as targeted delivery vehicles for radiosensitizing agents. In this work, the therapeutic benefits of high-Z NPs as radiosensitizers, such as their tumor-targeting capabilities and their mechanisms of sensitization, are discussed. Preclinical data supporting their application in radiotherapy treatment as well as the status of their clinical translation will be presented.

1 December 2006 in Medical Dosimetry
Verified
Journal Article
Closed access
CPCarmen C. Popescu
Carmen C. Popescu
IOIvo Olivotto
Ivo Olivotto
VPVeronica Patenaude
Veronica Patenaude
EWElaine Wai
Elaine Wai
WBWayne A Beckham
Wayne A Beckham

19 October 2023 in Cancer Nanotechnology
Verified
Journal Article
Open access
PDF file
KBKyle Bromma
Kyle Bromma
WBWayne A Beckham
Wayne A Beckham
DCDevika Chithrani
Devika Chithrani
Background: Much in vitro research on the applicability of gold nanoparticles (GNPs) in cancer treatment has been focused on two-dimensional (2D) monolayer models. To improve this, we explored the effect of the combination of GNPs and docetaxel (DTX) with radiotherapy (RT) in a more complex three-dimensional (3D) spheroid that can better mimic a real tumour microenvironment. Methods: Two cell lines, prostate cancer LNCaP and cervical cancer HeLa, were grown in monolayer and spheroids. Cells were dosed with GNPs at a concentration of 10 $$\mathrm{\mu g}/\mathrm{mL}$$ μ g / mL and with DTX at a dose that inhibited growth-rate by 50%. Samples were irradiated 24 h after drug dosing with 2 Gy, 5 Gy, or 10 Gy using a 6 MV beam. Monolayer cells had the DNA double-strand breaks (DSBs) probed 24 h post-radiation, and cell proliferation observed over 7 days. Spheroid proliferation was monitored over 14 days along with spheroid volume measurements. Results: In DTX and GNP-treated monolayer samples, there is decreased survival after irradiation with 5 and 10 Gy of 16–24% and an increase in DSBs of 91.6–109.9%, compared to DTX. In spheroids, GNPs decreased the surviving cells by 10.54–15.61% compared to control, while GNPs and DTX decreased survival by 20.9–31.04%. There is reduced spheroid volume 14 days after treatment with the triple combination. Conclusions: Combining GNPs and DTX leads to a synergistic radiosensitization effect in spheroids, which can better mimic the tumour microenvironment. Testing treatment modalities with spheroids and RT may allow a quicker translation to the clinic.